Industry cautions over probe into use of NICE approved drugs
September 10, 2009Sales and Marketing NICE, hc
The UK pharma industry has urged caution over data collected on the use of NICE-approved drugs on the NHS that …
Careers Voice: Making training work
September 10, 2009Business Services careers, careers voice, training
A senior manager in a major pharmaceutical company told me that the industry spends millions on training and next to …
Expanding clinical trials in India: answering the need for training
September 8, 2009Research and Development India, clinical trials
India is widely seen as the most exciting country in the clinical research world. Its potential to deliver large numbers …
Herceptin scientist wins Janssen award for biomedical research
September 8, 2009Research and Development Herceptin, Janssen
Johnson & Johnson has honoured the career achievements of Axel Ullrich by awarding him with the 2009 Dr Paul Janssen …
Observational studies will help answer growing safety demands
September 8, 2009Research and Development ICON, drug safety
The pharmaceutical industry is ready to adapt to growing drug safety requirements, but understanding of how it can capture safety …
OnMedica merges with MedSci
September 7, 2009Medical Communications, Sales and Marketing OnMedica, digi
Online PR company and medical education provider OnMedica Group has merged with medical communications company MedSci.The combined says it will …
Patients on Enbrel work longer, says study
September 7, 2009Research and Development, Sales and Marketing Enbrel, RA
Rheumatoid arthritis patients taking Enbrel are able to keep working for longer, according to a new study comparing its affects …
Blow for Irish pharma sector as Teva, Elan cut staff
September 7, 2009Manufacturing and Production Elan, Teva, lilly
Ireland’s pharmaceutical sector suffered a double blow last week as two drugmakers opted to make staff redundant at manufacturing plants …
NICE backs limited use of Lilly’s Plavix rival
September 7, 2009Research and Development Efient, NICE
NICE has recommended Lilly and Daiichi’s Efient for use on the NHS, giving the blood-thinner drug a boost in its …
Roche and PTC sign CNS research deal
September 4, 2009Research and Development CNS, Roche
PTC Therapeutics has signed an early-stage drug discovery deal with Roche that will focus on treatments for central nervous system …
Cameron: Tories are ‘the party of the NHS’
September 4, 2009NHS, US
David Cameron has called the Conservatives the "party of the NHS," in an attempt to reassure voters the service is …
Head-to-head boost for Brilinta over Plavix
September 4, 2009Research and Development, Sales and Marketing AZ, Brillinta
AstraZeneca has released details of its brand Brilinta’s performance in head-to-head trials with Plavix, the world’s second biggest-selling drug.Earlier this …
Roche’s MabThera expands licence in leukaemia
September 4, 2009Research and Development, Sales and Marketing MabThera, Roche
MabThera has been approved in Europe for use in previously treated chronic lymphocytic leukaemia, which Roche says will offer new …
Merck launches Saflutan in first European markets
September 4, 2009Research and Development, Sales and Marketing Merck, ophthalmology
Merck's glaucoma drug Saflutan has been launched in the UK and Spain. The manufacturer says more launches are planned in …
Novartis swine-flu jab effective in single dose
September 3, 2009Manufacturing and Production, Research and Development, Sales and Marketing Novartis, h1n1
A study of Novartis' pandemic swine-flu jab shows it is potentially protective after just one dose, which could help eke …
Pharmafocus expands into Europe
September 3, 2009Research and Development, Sales and Marketing Europe
The September issue of Pharmafocus marks a new stage in the publication’s development with an expanded monthly circulation that takes …
Merck unveils post-merger leadership team
September 3, 2009Research and Development, Sales and Marketing MA, Merck
The make-up of Merck and Schering-Plough's new corporate entity became clearer this week. Referred to as the 'new Merck' and …
Pfizer shamed with $2.3bn fine for marketing fraud
September 3, 2009Sales and Marketing Pfizer, US, illegal, off label prescribing
The US government has imposed a $2.3 billion fine on Pfizer for a string of offences including illegal off-label prescribing …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
